Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

In the Phase III REGENCY study, Gazyva elicited superior complete renal response rates in patients with lupus nephritis ...

Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection. Sanofi and Regeneron’s Dupixent is gearing up ...

ARCH Venture Partners is the latest venture capital firm to raise a multi-billion-dollar fund. The cash will be used to ...

During the job application and interview process, candidates who lie to prospective employers and those who don’t properly ...

In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and ...

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

A retrospective cohort study of more than 33,000 patients with type 2 diabetes showed that Novo Nordisk’s GLP-1 may lower the risk of opioid overdose by 42% to up to 68%.